Epacadostat Overcomes Cetuximab Resistance in Colorectal Cancer by Targeting IDO-Mediated Tryptophan Metabolism

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• RAS/RAF mutations cause cetuximab resistance in colorectal cancer (CRC), limiting treatment efficacy.
• The underlying mechanisms of cetuximab resistance in CRC are not fully understood.
• Identifying novel therapeutic strategies is crucial for overcoming treatment resistance.

Purpose of the Study:

• To investigate the mechanisms of cetuximab resistance in CRC.
• To evaluate the therapeutic potential of combining cetuximab with epacadostat, an indoleamine 2,3-dioxygenase (IDO) inhibitor.
• To explore the impact of this combination therapy on the tumor microenvironment and immune response.

Main Methods:

• RNA sequencing of cetuximab-sensitive and -resistant CRC specimens.
• In vitro and in vivo experiments using CRC cell lines and animal models.
• Analysis of tryptophan pathway metabolites, including kynurenine and tryptophan.
• Assessment of immune cell infiltration (CD8+ T lymphocytes, M1 macrophages) and cytokine profiles (IFN-γ).

Main Results:

• Cetuximab resistance was associated with tryptophan pathway activation and elevated IDO1/IDO2 expression.
• Epacadostat inhibited migration, proliferation, and induced apoptosis in cetuximab-resistant CRC cells.
• Combination therapy demonstrated synergistic anti-tumor effects, suppressing tumor growth more effectively than monotherapy.
• The combination therapy modulated the tumor microenvironment by reducing kynurenine, increasing CD8+ T cell infiltration, and promoting M1 macrophage polarization.

Conclusions:

• The tryptophan pathway, specifically IDO1/IDO2, plays a critical role in cetuximab resistance in CRC.
• Combining cetuximab with the IDO inhibitor epacadostat is a promising strategy to overcome cetuximab resistance.
• This combination therapy exerts potent anti-tumor effects by modulating the tumor microenvironment and enhancing anti-tumor immunity.